liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Tolvaptan Can Improve Clinical Course in Responders Validation Analysis for the Definition of Responsiveness by Urine Volume
University of Tokyo, Japan .
University of Tokyo, Japan .
University of Tokyo, Japan .
University of Tokyo, Japan .
Show others and affiliations
2013 (English)In: International Heart Journal, ISSN 1349-2365, Vol. 54, no 6, 377-381 p.Article in journal (Refereed) Published
Abstract [en]

We previously defined "responders" as patients with increases in urine volume (UV) on day 1 after the administration of tolvaptan (TLV), and demonstrated that responders to TLV could be predicted with considerable accuracy by urine osmolality (U-OSM) levels. Responders and non-responders to TLV should be associated with different clinical courses after a certain time following TLV administration. Therefore, the aim of the present study was to validate our definition of responders by clinical parameters 1 week after administration of TLV. Data (n = 85) were obtained from in-hospital patients with decompensated heart failure (HF) who had received TLV at 3.75-15 mg daily, and clinical data at 1 week after the administration of Thy were compared with those of baseline. Sixty patients (70.6%) were "responders", in whom UV on day 1 increased after the administration of TLV compared with day 0. "Non-responders" were older, and had higher serum creatinine concentration and lower baseline U-OSM than "responders". Serum creatinine concentration increased significantly in "non-responders", but was unchanged in "responders". Body weight, plasma B-type natriuretic peptide concentration, and HF symptom score decreased significantly in "responders", but remained unchanged in "non-responders". Increases in UV after the first administration of TLV were closely correlated with improvement of congestive HF after 1 week of TLV treatment, which verified our definition of "responders" to TLV.

Place, publisher, year, edition, pages
International Heart Journal Association , 2013. Vol. 54, no 6, 377-381 p.
Keyword [en]
Vasopressin; Heart failure; Urine osmolality
National Category
Health Sciences
URN: urn:nbn:se:liu:diva-111178DOI: 10.1536/ihj.54.377ISI: 000330147100007OAI: diva2:754543

Funding Agencies|Japan Society for the Promotion of Science [224943]; Japanese Heart Foundation; Japanese Association for Cerebro-Cardiovascular Disease Control; AstraZeneca; Pfizer Health Research Foundation

Available from: 2014-10-10 Created: 2014-10-10 Last updated: 2014-10-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Kato, Naoko
In the same journal
International Heart Journal
Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 80 hits
ReferencesLink to record
Permanent link

Direct link